Heparin neutralization with platelet factor 4 fragments
    2.
    发明授权
    Heparin neutralization with platelet factor 4 fragments 失效
    肝素中和与血小板因子4片段

    公开(公告)号:US5482923A

    公开(公告)日:1996-01-09

    申请号:US48812

    申请日:1993-04-16

    IPC分类号: A61K38/19 A61K38/36 A61K38/08

    CPC分类号: A61K38/195

    摘要: Circulating heparin in a mammal may be neutralized without substantial depletion of platelets or leukocytes by administering to the mammal a heparin neutralizing amount of a purified heparin binding fragment of PF4 or of recombinant PF4.

    摘要翻译: 通过向哺乳动物施用肝素中和量的PF4或重组PF4的纯化肝素结合片段,可以中和哺乳动物中的循环肝素,而不会明显损耗血小板或白细胞。

    Advantageous Salts of Mu-Opiate Receptor Peptides
    3.
    发明申请
    Advantageous Salts of Mu-Opiate Receptor Peptides 审中-公开
    Mu-Opiate受体肽的有利盐

    公开(公告)号:US20110190214A1

    公开(公告)日:2011-08-04

    申请号:US12744859

    申请日:2008-12-15

    CPC分类号: C07K5/1016 A61K38/00 C07K5/10

    摘要: The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their crystal structure, stability, solubility, lack of impurities and/or the ability to be produced, with these advantageous properties, in amounts sufficient for the production of therapeutic compositions.

    摘要翻译: 本发明提供了有利的mu-阿片受体肽的新盐。 已经发现,这些盐在它们的晶体结构,稳定性,溶解性,缺乏杂质和/或生产能力方面具有优异的性能,具有这些有利的性质,其用量足以制备治疗组合物。